In a filing, Taysha Gene Therapies Inc revealed its 10% Owner Manning Paul B acquired Company’s shares for reported $2.06 million on May 30 ’25. In the deal valued at $2.75 per share,750,000 shares were bought. As a result of this transaction, Manning Paul B now holds 2,841,704 shares worth roughly $7.96 million.
Then, Manning Paul B bought 1,333,333 shares, generating $2,999,999 in total proceeds. Upon buying the shares at $2.25, the 10% Owner now owns 1,333,333 shares.
BMO Capital Markets initiated its Taysha Gene Therapies Inc [TSHA] rating to an Outperform in a research note published on June 27, 2024; the price target was $5. A number of analysts have revised their coverage, including Piper Sandler’s analysts, who began to cover the stock in early April with a ‘”an Overweight”‘ rating. Jefferies also remained covering TSHA and has decreased its forecast on February 01, 2023 with a “Hold” recommendation from previously “Buy” rating. Morgan Stanley revised its rating on January 27, 2023. It rated TSHA as “an Equal-weight” which previously was an “an Overweight”.
Price Performance Review of TSHA
On Friday, Taysha Gene Therapies Inc [NASDAQ:TSHA] saw its stock fall -1.41% to $2.80. Over the last five days, the stock has gained 0.54%. Taysha Gene Therapies Inc shares have risen nearly 61.85% since the year began. Nevertheless, the stocks have fallen -29.82% over the past one year.
Levels Of Support And Resistance For TSHA Stock
How much short interest is there in Taysha Gene Therapies Inc?
A steep rise in short interest was recorded in Taysha Gene Therapies Inc stocks on 2025-05-15, growing by 3.09 million shares to a total of 26.24 million shares. Yahoo Finance data shows the prior-month short interest on 2025-04-15 was 23.15 million shares. There was a rise of 11.77%, which implies that there is a positive sentiment for the stock.
